Literature DB >> 31591698

[Test methods to determine magnetic resonance (MR) safety and MR image compatibility of implants/devices].

Gregor Schaefers1,2.   

Abstract

METHODICAL INNOVATIONS: In the present article, interactions associated with magnetic resonance (MR) procedures and MR test procedures for implants/devices are examined. PERFORMANCE: Since 2012, many interactions of items with MR procedures have been physically described and translated into standardized ASTM and ISO testing procedures. Despite the standardized procedures, the determination of the test method to use is an important decision. The MR user is also responsible for the transfer and interpretation of the individual technical parameters despite the MR Conditional labelling and therefore relatively unambiguous instruction. This includes the total MR examination duration, which often has no clinical practical duration, but is derived from the 15 min of the ASTM radiofrequency (RF) heating test. ACHIEVEMENTS: There has been an increasing standardization of the test methods as well as the MR labeling requirements and the advantageous transfer of the parameters to suitable input masks on the MR systems. PRACTICAL RECOMMENDATIONS: The current use of standardized MR test methods and MR marking represents the best possible state of the art from the point of view of the approval of medical devices as well as from a liability point of view for the manufacturers of implants-and for MR users in clinical practice. However, off-label decisions (i.e., deviations from the manufacturer's official MR marking) in everyday clinical practice can be medically justified.

Entities:  

Keywords:  Implants; MR safety; MR testing methods; MRI; RF heating

Mesh:

Year:  2019        PMID: 31591698     DOI: 10.1007/s00117-019-00588-y

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  7 in total

1.  MR labeling information for implants and devices: explanation of terminology.

Authors:  Frank G Shellock; Terry O Woods; John V Crues
Journal:  Radiology       Date:  2009-10       Impact factor: 11.105

2.  [Explanation of JIS T 62570 Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment].

Authors:  Toru Shimizu
Journal:  Nihon Hoshasen Gijutsu Gakkai Zasshi       Date:  2018

3.  ACR guidance document on MR safe practices: 2013.

Authors:  Emanuel Kanal; A James Barkovich; Charlotte Bell; James P Borgstede; William G Bradley; Jerry W Froelich; J Rod Gimbel; John W Gosbee; Ellisa Kuhni-Kaminski; Paul A Larson; James W Lester; John Nyenhuis; Daniel Joe Schaefer; Elizabeth A Sebek; Jeffrey Weinreb; Bruce L Wilkoff; Terry O Woods; Leonard Lucey; Dina Hernandez
Journal:  J Magn Reson Imaging       Date:  2013-01-23       Impact factor: 4.813

4.  The European Federation of Organisations for Medical Physics Policy Statement No 14: the role of the Medical Physicist in the management of safety within the magnetic resonance imaging environment: EFOMP recommendations.

Authors:  J Hand; H Bosmans; C Caruana; S Keevil; D G Norris; R Padovani; O Speck
Journal:  Phys Med       Date:  2013-01-09       Impact factor: 2.685

5.  Thermal tissue damage model analyzed for different whole-body SAR and scan durations for standard MR body coils.

Authors:  Manuel Murbach; Esra Neufeld; Myles Capstick; Wolfgang Kainz; David O Brunner; Theodoros Samaras; Klaas P Pruessmann; Niels Kuster
Journal:  Magn Reson Med       Date:  2013-02-14       Impact factor: 4.668

Review 6.  Summary, conclusions and recommendations: adverse temperature levels in the human body.

Authors:  L S Goldstein; M W Dewhirst; M Repacholi; L Kheifets
Journal:  Int J Hyperthermia       Date:  2003 May-Jun       Impact factor: 3.914

7.  CEM43°C thermal dose thresholds: a potential guide for magnetic resonance radiofrequency exposure levels?

Authors:  Gerard C van Rhoon; Theodoros Samaras; Pavel S Yarmolenko; Mark W Dewhirst; Esra Neufeld; Niels Kuster
Journal:  Eur Radiol       Date:  2013-04-04       Impact factor: 5.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.